Company Anacor Pharmaceuticals Inc
Equities
US0324201013
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
2016 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
2016 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Douglas Giordano
CEO | Chief Executive Officer | 61 | 23/06/16 |
Chief Tech/Sci/R&D Officer | 77 | 31/01/04 | |
Director/Board Member | - | 23/06/16 | |
General Counsel | 75 | 31/12/09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Giordano
CEO | Chief Executive Officer | 61 | 23/06/16 |
Bryan Supran
BRD | Director/Board Member | - | 23/06/16 |
Director/Board Member | - | 23/06/16 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 45,366,886 | 42,957,738 ( 94.69 %) | 0 | 94.69 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- Stock
- Company Anacor Pharmaceuticals Inc